Title: Collaborative Approaches to the Treatment of Chronic Myelogenous Leukemia
Locations: Live Grand Rounds Series

Learning Objectives:
• Differentiate among the safety, tolerability, and clinical outcomes of available BCR-ABL tyrosine kinase inhibitors for the first- and second-line treatment of chronic myelogenous leukemia (CML)
• Identify treatment response criteria and implement consensus response monitoring and cytogenetic/molecular testing guidelines
• Evaluate the latest clinical data on the treatment of resistant disease in the third line setting and beyond
• Identify, prevent, and manage drug and disease related side effects to minimize treatment modifications and discontinuations
• Explain best practices for engaging patients with CML to make more informed treatment decisions and improve adherence to oral therapy

Target Audience: This activity is designed for medical oncologists, hematologists, oncology nurses, and other healthcare professionals involved in the care and treatment of patients who have chronic myelogenous leukemia.

Program Overview: The goal of this activity is to provide clinicians with the latest clinical advances and emerging research in chronic myelogenous leukemia and strategies to optimally integrate evolving evidence into clinical practice to improve the quality-of-care delivery.

Faculty:

Michael W.N. Deininger, MD, PhD
Professor and Chief of Hematology and Hematologic Malignancies
Adjunct Professor, Department of Oncological Sciences
Senior Director of Transdisciplinary Research
 Huntsman Cancer Institute at the University of Utah
Salt Lake City

Physician Continuing Medical Education: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association
(CPEA) and AXIS Medical Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

**Physician Credit Designation Statement:**
Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure of Conflicts of Interest:**
Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

**Commercial Support:** This activity is supported by an educational grant from Novartis Pharmaceuticals.